Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
15 mars 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
09 mars 2017 16h01 HE
|
Zogenix, Inc.
Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox...
Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9
02 mars 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
01 mars 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference
15 févr. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
13 févr. 2017 08h00 HE
|
Zogenix, Inc.
Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada EMERYVILLE, Calif., Feb. 13, 2017 (GLOBE...
Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
08 févr. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
30 janv. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces CFO Transition
05 janv. 2017 16h01 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome
05 déc. 2016 08h00 HE
|
Zogenix, Inc.
New Clinical Data Presented at 70th Annual American Epilepsy Society MeetingPosters Highlighting Potential Protective Effect of ZX008 in Pre-Clinical Model of Sudden Unexpected Death in Epilepsy...